Where does Oruka Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Research and development	$100.64M-19.2%	$124.62M+12,202%	$1.01M-78.7%	$4.75M-65.7%
General and administrative	$21.41M+0.5%	$21.31M+239%	$6.28M+7.5%	$5.85M+6.3%
Compensation and benefits	$24.24M-5.1%	$25.54M—	——	——
Occupancy and equipment	$900K—	——	——	——
Other operating expenses	$122.05M-16.4%	$145.93M+1,900%	$7.3M-31.1%	$10.6M-45.2%
Total operating expenses	$122.05M-16.4%	$145.93M+1,900%	$7.3M-31.1%	$10.6M-45.2%
Operating income	-$122.05M+16.4%	-$145.93M-1,900%	-$7.3M+31.1%	-$10.6M+45.2%
Interest income	$16.63M+105%	$8.11M+314%	$1.96M+190%	$675K+5,092%
Other income (expense), net	$16.62M+290%	$4.26M—	——	——
Net income	-$105.43M+25.6%	-$141.67M-2,553%	-$5.34M+46.2%	-$9.93M+48.6%
Costs And Expenses Related Party	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$5M—	——	——	——
Share-based compensation expense related to employee stock plans	$14.18M+113%	$6.65M—	——	——
Issuance of warrants to purchase common stock	$10.07M—	——	——	——
Pre-tax stock-based compensation cost	$24.24M-1.8%	$24.69M—	——	——
Stock options excluded as their inclusion would be anti-dilutive (in shares)	35.3M+12.4%	31.4M—	——	——
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect	-$14.64M-103%	$515.31M—	——	——
Class Of Warrant Or Right To Purchase Percentage Of Outstanding Diluted Stock Maximum	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$104.85M+26.0%	-$141.71M—	——	——
Conversion Of Series A Nonvoting Convertible Preferred Stock To Common Stock	——	——	——	——
Depreciation	$83K—	——	——	——
Income taxes at U.S. statutory rate of 21%	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——
Nontaxable or nondeductible items	——	——	——	——
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——
Exchange Of Series A Convertible Preferred Stock For Series B Nonvoting Convertible Preferred Stock Upon The Closing Of The Reverse Capitalization	——	——	——	——
FDIC assessments	$250K—	——	——	——
Income Loss From Continuing Operations Before Income Taxes Domestic	-$105.43M—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$23.34M—	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	-$22.14M—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$2.11M—	——	——	——
Income Tax Reconciliation Worldwide Changes In Unrecognized Tax Benefits	——	——	——	——
Increase Decrease In Accounts Payable Related Parties	-$6.01M-118%	$33.65M—	——	——
Increase in accrued expenses and other liabilities	——	$6.4M+1,316%	-$526K+43.7%	-$934K—
Short- and long-term operating lease liabilities	-$468K—	——	——	——
Increase Decrease In Other Accounts Payable	$693K-90.3%	$7.11M—	——	——
Increase (decrease) in other assets	——	——	-$6K—	$0-100%
Increase (Decrease) in Prepaid Expense and Other Assets	$3.97M—	——	——	——
Issuance Cost Of The2025PIPE Financing	-$10.36M—	——	——	——
Issuance Costs Of PIPE Financing	——	——	——	——
Issuance Of Common Stock Series A Nonvoting Convertible Preferred Stock And Prefunded Warrants In Connection With Pipe Financing	——	——	——	——
Issuance Of Common Stock To Former Stockholders Of ARCA Biopharma Inc In Connection With The Closingof Reverse Capitalization	——	——	——	——
Issuance Of Common Stock Under Employee Stock Purchase Plan And Exercise Of Options And Warr	$294K—	——	——	——
Maximum Amount Of Stock Employees Eligible For Compensation	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	——	$953.84M—	——	$0—
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$96.75M+70.7%	-$330.3M—	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$88.21M+18.5%	-$108.23M-2,058%	-$5.01M+54.1%	-$10.91M+41.8%
Non Cash Lease Expense	——	——	——	——
Non Refundable License Fee	——	——	——	——
Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1	——	——	——	——
Number of reportable segments	——	——	——	——
Occupancy and Related Charges	——	——	——	——
Operating Lease Payments	$700K—	——	——	——
Other income, net (Note 6)	——	——	——	——
Paid-in-kind interest capitalized	——	——	——	——
Payments to Acquire Marketable Securities	$520.96M—	——	——	——
Payments to Acquire Property, Plant, and Equipment	$209K—	——	$0—	——
Proceeds From Atthemarket Offering Net Of Commissions	——	——	——	——
Proceeds from Issuance of Common Stock	——	——	——	——
Proceeds from maturities of marketable securities	$424.42M—	——	——	——
Reclassification Of The Paruka Warrant From Liability To Equity	$10.07M—	——	——	——
Stock-based compensation	$24.24M-5.1%	$25.54M+3,623%	$686K+23.4%	$556K+11.9%
Granted (in shares)	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period	——	——	——	——
Options canceled (in dollars per share)	——	——	——	——
Granted (in shares)	——	——	——	——
Exercised (in shares)	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	——	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	——	——	——	——
Stock Issued During Period, Value, Stock Options Exercised	——	——	——	——
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions	$123K—	——	——	——
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions	$895K—	——	——	——
Increase (decrease) in amount of unrecognized tax benefits	$91K—	——	——	——
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$27.4M—	——	——	——
EBIT	-$122.05M+16.4%	-$145.93M-1,900%	-$7.3M+31.1%	-$10.6M+45.2%
EBITDA	-$121.97M+16.4%	-$145.88M-1,904%	-$7.28M+31.2%	-$10.58M+45.3%
EBITDA	-$121.97M+16.4%	-$145.88M-1,904%	-$7.28M+31.2%	-$10.58M+45.3%
EBIT	-$122.05M+16.4%	-$145.93M-1,900%	-$7.3M+31.1%	-$10.6M+45.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Oruka Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.